MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Amgen News Service' source. Thu, 18 Mar 2010 15:15:56 +0100 http://www.medworm.com/index.php?rid=3289798&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_classifies_proliatm_denosumab_complete_response_submission_and_targets_%2F THOUSAND OAKS, Calif., Feb 19, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company’s Complete Response submission for Prolia(TM) (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3289798 Fri, 19 Feb 2010 00:00:00 +0100 3289798 http://www.medworm.com/index.php?rid=3289799&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_centocor_ortho_biotech_products_finalize_esa_risk_evaluation_and_%2F THOUSAND OAKS, Calif., Feb 16, 2010 /PRNewswire via COMTEX/—Amgen Inc.  (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa) and PROCRIT(R) (Epoetin alfa). The FDA has determined that a REMS is necessary for ESAs to ensure the benefits of these drugs outweigh the risks of shortened overall survival and/or increased tumor progression or recurrence as identified in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid and cervical cancers. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3289799 Tue, 16 Feb 2010 00:00:00 +0100 3289799 http://www.medworm.com/index.php?rid=3257065&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_study_published_in_the_lancet_oncology_demonstrated_86_percent_tu%2F THOUSAND OAKS, Calif. (February 9, 2010) – Amgen (NASDAQ: AMGN) issued the following statement on the publication of results online today by the Lancet Oncology. For a summary of the manuscript click here. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3257065 Tue, 09 Feb 2010 00:00:00 +0100 3257065 http://www.medworm.com/index.php?rid=3261141&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrated_superiority_over_zometar_in_pivotal_phase_3_head_to_%2F THOUSAND OAKS, Calif., Feb 08, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and reducing the rate of multiple SREs (hazard ratio 0.82, 95 percent CI: 0.71, 0.94). Both results were statistically significant. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3261141 Mon, 08 Feb 2010 00:00:00 +0100 3261141 http://www.medworm.com/index.php?rid=3261142&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_fourth_quarter_2009_adjusted_earnings_per_share_decreased_1_percent_%2F THOUSAND OAKS, Calif., Jan 25, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.05 for the fourth quarter of 2009, a decrease of 1 percent compared to $1.06 for the fourth quarter of 2008. Adjusted net income decreased 5 percent to $1,065 million in the fourth quarter of 2009 compared to $1,124 million in the fourth quarter of 2008. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3261142 Mon, 25 Jan 2010 00:00:00 +0100 3261142 http://www.medworm.com/index.php?rid=3261143&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_presents_complete_results_from_two_pivotal_phase_3_studies_of_vectibi%2F THOUSAND OAKS, Calif., Jan 21, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME ‘203’ and ‘181’ trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3261143 Thu, 21 Jan 2010 00:00:00 +0100 3261143 http://www.medworm.com/index.php?rid=3261144&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2009_fourth_quarter_and_full_year_financial_resu%2F THOUSAND OAKS, Calif., Jan 20, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3261144 Wed, 20 Jan 2010 00:00:00 +0100 3261144 http://www.medworm.com/index.php?rid=3261145&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_donates_2_million_establishes_earthquake_relief_program%2F THOUSAND OAKS, Calif., Jan 14, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq:  AMGN) today announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3261145 Thu, 14 Jan 2010 00:00:00 +0100 3261145 http://www.medworm.com/index.php?rid=3098734&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_receives_chmp_positive_opinion_for_proliatm_denosumab_in_the_european%2F THOUSAND OAKS, Calif. – Dec 18, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. If approved by the European Commission, Amgen would receive marketing authorization for Prolia in all European Union (EU) Member States. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3098734 Fri, 18 Dec 2009 00:00:00 +0100 3098734 http://www.medworm.com/index.php?rid=3094713&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_issues_statement_on_update_to_us_prescribing_information_for_erythrop%2F On December 16, 2009, Amgen updated the boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), to reflect an increased risk of stroke when ESAs are administered to chronic renal failure patients to target hemoglobin levels of 13 g/dL and above. The update was made based on results from the recently completed clinical study, TREAT (the Trial to Reduce Cardiovascular Events with Aranesp Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. In addition, the Warnings section has been updated to include a description of TREAT and t... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3094713 Wed, 16 Dec 2009 00:00:00 +0100 3094713 http://www.medworm.com/index.php?rid=3054831&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_amgen_scholars_web_site_launches_to_build_a_global_network_for_future_s%2F THOUSAND OAKS, Calif. (Dec. 3, 2009) – Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world’s leading universities.  Now, the Amgen Scholars – past, present and future – will have exclusive access to the online Amgen Scholars Community at www.amgenscholars.com. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3054831 Thu, 03 Dec 2009 00:00:00 +0100 3054831 http://www.medworm.com/index.php?rid=3054832&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_ash%2F THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate?? (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3054832 Mon, 30 Nov 2009 00:00:00 +0100 3054832 http://www.medworm.com/index.php?rid=3021379&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_recognized_for_best_pipeline_and_best_new_drug_at_scrip_awards%2F THOUSAND OAKS, Calif., Nov. 23—Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3021379 Mon, 23 Nov 2009 00:00:00 +0100 3021379 http://www.medworm.com/index.php?rid=3006415&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_lazard_capital_healthcare_conference%2F THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006415 Mon, 16 Nov 2009 00:00:00 +0100 3006415 http://www.medworm.com/index.php?rid=3006416&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_18th_annual_credit_suisse_healthcare_conference%2F THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006416 Thu, 12 Nov 2009 00:00:00 +0100 3006416 http://www.medworm.com/index.php?rid=3006417&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_overall_survival_results_for_vectibixr_in_first_line_metast%2F THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.  Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006417 Thu, 05 Nov 2009 00:00:00 +0100 3006417 http://www.medworm.com/index.php?rid=3006418&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fcall_for_applications_the_amgen_award_for_science_teaching_excellence1%2F THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE).  This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006418 Wed, 04 Nov 2009 00:00:00 +0100 3006418 http://www.medworm.com/index.php?rid=3006419&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Flarge_study_of_anemia_treatment_in_chronic_kidney_disease_patients_not_on_d%2F THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity, including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia, or end-stage renal disease (ESRD). (Source: Amgen News Service... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006419 Fri, 30 Oct 2009 00:00:00 +0100 3006419 http://www.medworm.com/index.php?rid=3006420&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_third_quarter_2009_adjusted_earnings_per_share_increased_21_percent_%2F THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=3006420 Wed, 21 Oct 2009 00:00:00 +0100 3006420 http://www.medworm.com/index.php?rid=2903943&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_provides_update_on_status_of_proliatm_denosumab_biologics_license_app%2F THOUSAND OAKS, Calif. – Oct 19, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis. The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval.  (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2903943 Sun, 18 Oct 2009 23:00:00 +0100 2903943 http://www.medworm.com/index.php?rid=2897148&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2009_third_quarter_financial_results%2F THOUSAND OAKS, Calif. – Oct. 15 – Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2897148 Wed, 14 Oct 2009 23:00:00 +0100 2897148 http://www.medworm.com/index.php?rid=2826777&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_in_combination_with_chemotherapy_significantly_improves_progressi%2F THOUSAND OAKS, Calif. – Sept 24, 2009 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘203’ trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 10LBA). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2826777 Wed, 23 Sep 2009 23:00:00 +0100 2826777 http://www.medworm.com/index.php?rid=2817498&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_in_combination_with_chemotherapy_significantly_improves_progressi%2F THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2817498 Mon, 21 Sep 2009 23:00:00 +0100 2817498 http://www.medworm.com/index.php?rid=2817497&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrates_superiority_over_zometar_in_delay_of_complications_d%2F THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 2LBA). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2817497 Mon, 21 Sep 2009 23:00:00 +0100 2817497 http://www.medworm.com/index.php?rid=2813673&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fphase_3_trial_shows_denosumab_delayed_skeletal_related_events_in_advanced_c%2F THOUSAND OAKS, Calif. – Sept. 21 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2813673 Sun, 20 Sep 2009 23:00:00 +0100 2813673 http://www.medworm.com/index.php?rid=2813674&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_ubs_global_life_sciences_conference%2F THOUSAND OAKS, Calif. – Sept. 17 – Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Monday, Sept. 21, 2009, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2813674 Wed, 16 Sep 2009 23:00:00 +0100 2813674 http://www.medworm.com/index.php?rid=2798955&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_scholars_europe_programme_convenes_undergraduates_from_15_countries_f%2F Symposium Offers Unique Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2798955 Tue, 15 Sep 2009 23:00:00 +0100 2798955 http://www.medworm.com/index.php?rid=2798954&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_pivotal_data_from_four_phase_3_studies_at_the_ecco_15_esmo%2F Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented: Amgen announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.  (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2798954 Tue, 15 Sep 2009 23:00:00 +0100 2798954 http://www.medworm.com/index.php?rid=2795124&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_bank_of_america_merrill_lynch_global_healthcare_con%2F THOUSAND OAKS, Calif. – Sept. 14 – Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 17, 2009, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2795124 Sun, 13 Sep 2009 23:00:00 +0100 2795124 http://www.medworm.com/index.php?rid=2795125&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdata_show_medication_adherence_is_an_important_factor_in_the_treatment_of_p%2F DENVER – Sept. 13 – Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2795125 Sat, 12 Sep 2009 23:00:00 +0100 2795125 http://www.medworm.com/index.php?rid=2787726&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_morgan_stanley_global_healthcare_unplugged_conferen%2F THOUSAND OAKS, Calif. – Sept. 11 – Amgen (Nasdaq: AMGN) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New York City, beginning at 12:00 p.m. Eastern Time. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2787726 Thu, 10 Sep 2009 23:00:00 +0100 2787726 http://www.medworm.com/index.php?rid=2784364&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_american_society_for_bone_and_mine%2F THOUSAND OAKS, Calif. – Sept. 10 – Amgen (Nasdaq: AMGN) today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009. Prolia currently is being evaluated by regulatory bodies in the United States (U.S.), the European Union, Switzerland, Australia and Canada as a potential therapy for postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation for prostate and breast cancer. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2784364 Wed, 09 Sep 2009 23:00:00 +0100 2784364 http://www.medworm.com/index.php?rid=2780636&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fthis_is_an_internal_title_only_will_not_published_128_characters_max1%2F LEWISTON, Maine and THOUSAND OAKS, Calif. – Sept. 9 – Amgen has signed on as the presenting sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and 5K fundraising event scheduled for October 4 in Lewiston, Maine. The event supports The Patrick Dempsey Center for Cancer Hope & Healing at Central Maine Medical Center. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2780636 Tue, 08 Sep 2009 23:00:00 +0100 2780636 http://www.medworm.com/index.php?rid=2780637&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_thomas_weisel_healthcare_conference%2F THOUSAND OAKS, Calif. – Sept. 8 – Amgen (Nasdaq: AMGN) will participate in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, at the Four Seasons in Boston, Mass. beginning at 8:35 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2780637 Mon, 07 Sep 2009 23:00:00 +0100 2780637 http://www.medworm.com/index.php?rid=2780638&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_baird_healthcare_conference%2F THOUSAND OAKS, Calif. – Sept. 4 – Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 10, 2009, at the Four Seasons in New York City, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development, for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2780638 Thu, 03 Sep 2009 23:00:00 +0100 2780638 http://www.medworm.com/index.php?rid=2780639&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ftim_gunn_hosts_addressing_psoriasistm_fashion_show_to_raise_awareness_of_ps%2F Eight Contest Winners Model Custom-Designed Outfits to Show that Moderate to Severe Plaque Psoriasis Does Not Impact Their Personal Style NEW YORK – Sept. 2 – Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn’s Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to severe plaque psoriasis who have not allowed the condition to inhibit their personal style. Winners of the Addressing Psoriasis(TM) contest are walking the runway in custom-designed outfits created by emerging talent from the Fashion Institute of Technology (FIT) to help raise public awareness of ... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2780639 Tue, 01 Sep 2009 23:00:00 +0100 2780639 http://www.medworm.com/index.php?rid=2732525&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_top_line_results_of_trial_to_reduce_cardiovascular_events_w%2F THOUSAND OAKS, Calif.—Aug. 25—Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type 2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp(R) (darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2732525 Mon, 24 Aug 2009 23:00:00 +0100 2732525 http://www.medworm.com/index.php?rid=2707202&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_significantly_improved_progression_free_survival_in_second_line_t%2F Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show Progression-Free Survival Advantage in KRAS Wild-Type Population THOUSAND OAKS, Calif. – Aug. 17 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2707202 Sun, 16 Aug 2009 23:00:00 +0100 2707202 http://www.medworm.com/index.php?rid=2697978&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_discuss_denosumab_data_at_todays_advisory_committee_for_reproducti%2F  Committee to Review Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation Therapy for Either Prostate or Breast Cancer THOUSAND OAKS, Calif. – Aug 13, 2009 – Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer patients undergoing hormone ablation at a meeting with the U.S. Food and Drug Administration’s (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2697978 Wed, 12 Aug 2009 23:00:00 +0100 2697978 http://www.medworm.com/index.php?rid=2697977&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_issues_statement_on_outcomes_of_advisory_committee_for_reproductive_h%2F THOUSAND OAKS, Calif. – Aug 13, 2009 – Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today’s meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast cancer. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2697977 Wed, 12 Aug 2009 23:00:00 +0100 2697977 http://www.medworm.com/index.php?rid=2690213&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fstudies_published_in_the_new_england_journal_of_medicine_highlight_potentia%2F Twice-Yearly Administration of Denosumab Resulted in 68 Percent Reduction in Risk for a Vertebral Fracture and 40 Percent Reduction in Risk for a Hip Fracture in Women with Postmenopausal Osteoporosis Denosumab Administered Twice-Yearly Reduced the Incidence of New Vertebral Fractures by 62 Percent in Men with Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy     THOUSAND OAKS, Calif. – Aug. 11 /PRNewswire-FirstCall – Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing andr... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2690213 Mon, 10 Aug 2009 23:00:00 +0100 2690213 http://www.medworm.com/index.php?rid=2677112&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_in_combination_with_chemotherapy_significantly_improved_progressi%2F Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population Phase 3 Results Reinforce Importance of KRAS Testing THOUSAND OAKS, Calif. – Aug. 6 – Amgen (Nasdaq: AMGN) today announced that Vectibix (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2677112 Wed, 05 Aug 2009 23:00:00 +0100 2677112 http://www.medworm.com/index.php?rid=2665994&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_positive_top_line_results_for_denosumab_in_trial_for_delay_%2F Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events THOUSAND OAKS, Calif. – Aug. 3 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2665994 Sun, 02 Aug 2009 23:00:00 +0100 2665994 http://www.medworm.com/index.php?rid=2659577&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_statement_on_passage_of_the_eshoo_inslee_barton_amendment_to_the_hous%2F The following statement was issued today by Amgen on the passage of the Eshoo-Inslee-Barton amendment to the House Energy & Commerce Committee’s health care reform legislation. The strong bipartisan support in the Energy and Commerce Committee for a fair and balanced pathway for the approval of biosimilars is a win for patients. The amendment introduced by Representatives Eshoo, Inslee and Barton and overwhelmingly approved by the Committee strikes a necessary balance in allowing access to safe and effective biosimilar medicines for patients, and providing fair incentives for the discovery of new medicines for serious diseases. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2659577 Thu, 30 Jul 2009 23:00:00 +0100 2659577 http://www.medworm.com/index.php?rid=2643585&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_second_quarter_2009_adjusted_earnings_per_share_increased_13_percent%2F Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to $4.80-$4.95 THOUSAND OAKS, Calif. –July 27 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.29 for the second quarter of 2009, an increase of 13 percent compared to$1.14 for the second quarter of 2008. Adjusted net income increased 6 percent to $1,311 million in the second quarter of 2009 compared to $1,235 million in the second quarter of 2008. (Source: Amgen News S... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2643585 Sun, 26 Jul 2009 23:00:00 +0100 2643585 http://www.medworm.com/index.php?rid=2643584&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_collaborate_with_glaxosmithkline_to_commercialize_denosumab_in_eur%2F Amgen to Retain Full Rights for Denosumab in the United States and Canada and for Oncology Indications in Europe GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging Markets THOUSAND OAKS, Calif. and LONDON – July 27 – Amgen (Nasdaq: AMGN) andGlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) inEurope, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2643584 Sun, 26 Jul 2009 23:00:00 +0100 2643584 http://www.medworm.com/index.php?rid=2618776&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_scholars_discover_their_potential_during_summer_science_research_prog%2F THOUSAND OAKS, Calif. – July 20, 2009 – From July 18-20, more than 260 of the country’s brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2618776 Sun, 19 Jul 2009 23:00:00 +0100 2618776 http://www.medworm.com/index.php?rid=2612673&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_kras_safety_update_to_us_prescribing_information_for_vectib%2F Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr Antibody Monotherapy in Metastatic Colorectal Cancer Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in Combination Therapy Expected In Third Quarter 2009  THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). This decision follows the FDA’s December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated ... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2612673 Thu, 16 Jul 2009 23:00:00 +0100 2612673 http://www.medworm.com/index.php?rid=2586543&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_rebecca_m_henderson_to_the_companys_board_of_directors%2F THOUSAND OAKS, Calif. – July 9 – Amgen (Nasdaq: AMGN) announced today that its Board of Directors has appointed Rebecca M. Henderson, Ph.D., to the Company’s Board. Dr. Henderson, 48, has recently joined the faculty at the Harvard Business School, having been the Eastman Kodak LFM Professor of Management at the Massachusetts Institute of Technology (MIT) Sloan School since 1999. She specializes in technology strategy and the broader strategic problems faced by firms in high technology industries. From 1995 to 1999, Dr. Henderson was a tenured associate professor at the MIT Sloan School. She has been a director of IDEXX Laboratories, Inc. since 2003. Dr. Henderson’s appointment brings the number of Amgen Board members to 13. Dr. Henderson will serve as a member of the Corpor... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2586543 Wed, 08 Jul 2009 23:00:00 +0100 2586543 http://www.medworm.com/index.php?rid=2578776&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrates_superiority_over_zometar_in_pivotal_phase_3_head_to_%2F Denosumab Significantly Delayed the Time to the First Skeletal Related Event and Significantly Reduced First and Subsequent Skeletal Related Events Compared to Zometa First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the Advanced Cancer Setting Meets Primary and Secondary Endpoints THOUSAND OAKS, Calif. – July 7 – Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. Superiority was demonstrated for both delaying the time to the first on-study Skeletal Related Events (SREs)(fracture, radiation to bone... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2578776 Mon, 06 Jul 2009 23:00:00 +0100 2578776 http://www.medworm.com/index.php?rid=2578777&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fwinners_of_the_addressing_psoriasistm_contest_selected_to_walk_the_runway_i%2F NEW YORK – July 6 – Amgen and Wyeth today announced the eight winners of the Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who have tried not to allow the condition to inhibit their personal style. The winners will help raise public awareness of the condition by walking the runway in the Addressing Psoriasis(TM) Fashion Show hosted by television host and fashion consultant, Tim Gunn ("Project Runway," and "Tim Gunn’s Guide to Style"), on Sept. 2, 2009. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2578777 Sun, 05 Jul 2009 23:00:00 +0100 2578777 http://www.medworm.com/index.php?rid=2578778&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2F34_outstanding_teachers_and_schools_receive_10000_amgen_award_for_science_t%2F THOUSAND OAKS, Calif. – June 17, 2009 – Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year’s recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2578778 Tue, 16 Jun 2009 23:00:00 +0100 2578778 http://www.medworm.com/index.php?rid=2481898&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fstatement_in_response_to_ftc_report_on_biosimilars%2F THOUSAND OAKS, Calif.–June 10, 2009–As a biotechnology pioneer committed to developing first-in-class medicines that treat serious illnesses and unmet health needs, Amgen believes that an abbreviated biosimilar approval pathway must not discourage the development of groundbreaking new treatments for serious diseases.  (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2481898 Wed, 10 Jun 2009 04:00:00 +0100 2481898 http://www.medworm.com/index.php?rid=2466370&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_study_shows_nplater_significantly_reduces_splenectomy_rate_and_treatmen%2F BERLIN – June 7 – Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2466370 Mon, 08 Jun 2009 04:00:00 +0100 2466370 http://www.medworm.com/index.php?rid=2438243&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_survey_highlights_growing_concern_about_risk_of_infection_in_cancer_pat%2F Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population THOUSAND OAKS, Calif. – May 27, 2009 – Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to prevent infections to achieve successful treatment outcomes. Antibiotic resistance is a growing concern among the majority of physicians surveyed, with 96 percent of ID specia... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2438243 Wed, 27 May 2009 04:00:00 +0100 2438243 http://www.medworm.com/index.php?rid=2435210&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_exercises_option_for_exclusive_license_to_cytokinetics_cardiac_contra%2F Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/—Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics’ cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2435210 Tue, 26 May 2009 04:00:00 +0100 2435210 http://www.medworm.com/index.php?rid=2409821&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_asco1%2F New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif. – May 15 – Amgen (Nasdaq: AMGN) today announced it will present new data from the Company’s oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. fromMay 29 to June 2, 2009. Data will be presented from several programs, including Vectibix(R) (panitumumab), Neulasta(R) (pegfilgrastim), Aranesp(R) (darbepoetin alfa), denosumab, conatumumab (AMG 655), dulanermin (rhApo2L/TRAIL) and AMG 479. (Source: Amgen News ... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2409821 Fri, 15 May 2009 04:00:00 +0100 2409821 http://www.medworm.com/index.php?rid=2409822&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_deutsche_bank_34th_annual_healthcare_conference%2F THOUSAND OAKS, Calif. – May 13 – Amgen (Nasdaq: AMGN) will present at theDeutsche Bank 34th Annual Healthcare Conference on Monday, May 18, 2009 at the InterContinental,Boston, Mass., beginning at 9:20 a.m. Eastern Time. Chairman and Chief Executive Officer  Kevin Sharer will present. Live audio of the presentation will be available over the Internet and can be accessed fromAmgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2409822 Wed, 13 May 2009 04:00:00 +0100 2409822 http://www.medworm.com/index.php?rid=2409823&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_onsedge_partner_with_cancer_survivor_jan_ping_for_new_campaign%2F THOUSAND OAKS, Calif. – April 30 – Amgen and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced that they will partner alongside celebrity make-up artist and cancer survivor Jan Ping to support a new educational campaign, Coping with Cancer From the Outside In. The initiative is aimed at educating oncology nurses about the skin-related side effects associated with epidermal growth factor receptor (EGFR) inhibitors that are used to treat metastatic colorectal, lung, pancreatic, and head and neck cancers. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2409823 Thu, 30 Apr 2009 04:00:00 +0100 2409823 http://www.medworm.com/index.php?rid=2367486&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_wyeth_announce_enbrel_support_program%2F Amgen and Wyeth remain committed to helping to provide clinically appropriate patients access to Enbrel® (etanercept), despite tough economic times. Once physicians and their patients have determined that ENBREL is the right treatment choice, patients may benefit from the ENBREL Support™ program, which offers financial support to eligible patients in several ways, depending on their specific situation. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2367486 Fri, 24 Apr 2009 04:00:00 +0100 2367486 http://www.medworm.com/index.php?rid=2361771&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_first_quarter_2009_adjusted_earnings_per_share_decreased_4_percent_t%2F First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion  First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98 2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to $14.4 to $14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to $4.75   THOUSAND OAKS, Calif. – April 23 /– Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12for the first quarter of 2008. Adjusted net income decreased 8 percent to $1,120 million in the first quarter of 2009 compared to $1,218 million in the first quarter of 2008. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2361771 Thu, 23 Apr 2009 04:00:00 +0100 2361771 http://www.medworm.com/index.php?rid=2351829&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2009_first_quarter_financial_results%2F THOUSAND OAKS, Calif. – April 20 – Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Thursday, April 23, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2351829 Mon, 20 Apr 2009 04:00:00 +0100 2351829 http://www.medworm.com/index.php?rid=2336309&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_introduces_new_amgentrialscom%2F Amgen today launched the new Amgentrials.com website (http://www.amgentrials.com), an important resource for patients, physicians, and others who seek information about the company’s clinical trials. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2336309 Fri, 17 Apr 2009 04:00:00 +0100 2336309 http://www.medworm.com/index.php?rid=2336310&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fpreclinical_data_from_amgens_oncology_pipeline_to_be_presented_at_aacr%2F  Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF-A Amgen Launches Angiogenesis Website THOUSAND OAKS, Calif. – April 16 – Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22, 2009. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2336310 Thu, 16 Apr 2009 04:00:00 +0100 2336310 http://www.medworm.com/index.php?rid=2313896&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ftemp_headline%2F The following statement was issued by Amgen regarding a consensus agreement on patent reform legislation which was approved by the U.S Senate Judiciary Committee today: Patients facing life-threatening diseases—such as cancer, Alzheimer’s, Parkinson’s, and ALS— depend on the discovery and development of breakthrough treatments and cures. Strong and enforceable patents are essential in providing scientists and researchers the incentive to innovate in such a resource intensive field. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2313896 Thu, 02 Apr 2009 04:00:00 +0100 2313896 http://www.medworm.com/index.php?rid=2313897&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_citigroup_biotech_day%2F THOUSAND OAKS, Calif. – March 30 – Amgen (Nasdaq: AMGN) will present at Citigroup’s 4th Annual Biotech Day on Wednesday, April 1, 2009 at the Citigroup Conference Center, New York, N.Y., beginning at 11:20 a.m. Eastern Time. Amgen Vice President of Investor Relations Arvind Sood will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2313897 Mon, 30 Mar 2009 04:00:00 +0100 2313897 http://www.medworm.com/index.php?rid=2279613&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_statement_in_response_to_the_eshoo_inslee_barton_bill_to_establish_a%2F The following statement was issued today by Amgen regarding legislation introduced today by Representatives Eshoo, Inslee and Barton to establish a pathway for the approval of biosimilars. The legislation introduced by Representatives Eshoo, Inslee and Barton appears to strike a necessary balance in allowing access to safe and effective biosimilar medicines for patients, and providing fair incentives for the discovery of new medicines for serious diseases. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2279613 Tue, 17 Mar 2009 04:00:00 +0100 2279613 http://www.medworm.com/index.php?rid=2270951&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_cowen_and_company_annual_healthcare_conference%2F Amgen (NASDAQ:AMGN) will present at the Cowen and Company Annual Healthcare Conference on Wednesday, March 18, 2009 at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2270951 Mon, 16 Mar 2009 04:00:00 +0100 2270951 http://www.medworm.com/index.php?rid=2253526&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fstatement_in_response_to_chairman_waxmans_bill_to_establish_a_pathway_for_t%2F The following statement was issued today by Amgen regarding legislation introduced today by Chairman Waxman, Rep. Deal and Rep. Pallone to establish a pathway for the approval of biosimilars. As a pioneer in developing first-in-class medicines that treat serious illnesses and address unmet health needs, Amgen believes that an abbreviated biosimilar approval pathway must not discourage the development of groundbreaking new treatments for serious diseases. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2253526 Wed, 11 Mar 2009 04:00:00 +0100 2253526 http://www.medworm.com/index.php?rid=2253527&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_barclays_capital_global_healthcare_conference%2F THOUSAND OAKS, Calif. – March 9 – Amgen (Nasdaq: AMGN) will present at the Barclays Capital Global Healthcare Conference on Wednesday, March 11, 2009 at the Loews Miami Beach Hotel, Miami Beach, Fla., beginning at 9:00 a.m. Eastern Time. Amgen’s Chief Financial Officer Robert A. Bradway will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2253527 Mon, 09 Mar 2009 04:00:00 +0100 2253527 http://www.medworm.com/index.php?rid=2253528&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fproject_runways_tim_gunn_launches_addressing_psoriasistm_campaign_to_advoca%2F NEW YORK – March 4, 2009 – Amgen and Wyeth today announced that they have partnered with Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn’s Guide to Style") to launch Addressing Psoriasis(TM), an awareness campaign designed to help people with plaque psoriasis get more information about managing their disease and feel more confident in their everyday style. Dermatologist Susan C. Taylor, M.D., and Gunn are working together to encourage people with plaque psoriasis to visit a dermatologist and take the first step in managing their condition. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2253528 Wed, 04 Mar 2009 05:00:00 +0100 2253528 http://www.medworm.com/index.php?rid=2224648&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_statement_on_the_announcement_of_governor_gary_locke_as_commerce_secr%2F Governor Gary Locke, as President Obama’s nominee for Commerce Secretary, will bring to his new position, when confirmed, a sense of urgency about the economy and the central role of private sector growth will play in our economic recovery. While Governor, Gary Locke consistently pursued measures that advanced human health, fostered the development of new medicines, and help to growth the life science and biotechnology industry in the State of Washington.   (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2224648 Fri, 27 Feb 2009 05:00:00 +0100 2224648 http://www.medworm.com/index.php?rid=2224650&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_accepts_amgens_submission_and_files_biologics_license_application_for_d%2F THOUSAND OAKS, Calif. – Feb. 18 – Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen’s submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2224650 Wed, 18 Feb 2009 05:00:00 +0100 2224650 http://www.medworm.com/index.php?rid=2224652&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Findependent_data_monitoring_committee_recommends_resuming_enrollment_of_non%2F THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan – Feb. 12, 2009 – Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and its parent company Takeda Pharmaceutical Company Limited (TSE:4052) today announced the Independent Data Monitoring Committee (DMC) for the MONET1 trial has recommended the trial resume enrollment of patients with non-squamous non-small cell lung cancer (NSCLC) following a three-month enrollment suspension. MONET1 is a Phase 3 study evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced NSCLC. Motesanib is part of a co-development program between Amgen, Millennium and Takeda. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2224652 Wed, 11 Feb 2009 05:00:00 +0100 2224652 http://www.medworm.com/index.php?rid=2169050&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnplater_approved_in_the_european_union_for_the_treatment_of_chronic_immune_%2F ZUG, Switzerland – Feb. 6 – Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised ITP patients where surgery is contra-indicated. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2169050 Fri, 06 Feb 2009 05:00:00 +0100 2169050 http://www.medworm.com/index.php?rid=2135598&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_fourth_quarter_2008_adjusted_earnings_per_share_increased_6_percent_%2F Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 Billion Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91 2009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion 2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to $4.75   THOUSAND OAKS, Calif. – Jan. 26 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.06 for the fourth quarter of 2008, an increase of 6 percent compared to $1.00 for the fourth quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, increased 3 percent ... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2135598 Mon, 26 Jan 2009 05:00:00 +0100 2135598 http://www.medworm.com/index.php?rid=2135599&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_breakaway_from_cancer_initiative_expands_to_help_cancer_patients_acc%2F THOUSAND OAKS, Calif. – Jan. 22  – In an ongoing effort to raise awareness of the comprehensive continuum of resources available to cancer patients and their caregivers—from prevention to education, patient care to advocacy and financial support --Amgen’s Breakaway from Cancer(TM) initiative has expanded its charitable partners to now include the National Coalition for Cancer Survivorship, Patient Advocate Foundation, Prevent Cancer Foundation and The Wellness Community. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2135599 Thu, 22 Jan 2009 05:00:00 +0100 2135599 http://www.medworm.com/index.php?rid=2054885&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_submits_biologics_license_application_for_fda_approval_of_denosumab_i%2F THOUSAND OAKS, Calif. – Dec. 19 – Amgen Inc. (Nasdaq: AMGN), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The BLA submission contains data from six Phase 3 trials involving more than 11,000 patients. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054885 Fri, 19 Dec 2008 05:00:00 +0100 2054885 http://www.medworm.com/index.php?rid=2054886&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Foncology_biomarker_kras_to_be_discussed_at_fda_panel_meeting%2F THOUSAND OAKS, Calif. – Dec 16 – KRAS Biomarker Presents Potential to Personalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R) Amgen today announced they will discuss the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054886 Tue, 16 Dec 2008 05:00:00 +0100 2054886 http://www.medworm.com/index.php?rid=2054887&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Flong_term_follow_up_interim_data_show_nplatetm_increased_and_sustained_plat%2F SAN FRANCISCO – Dec 08 – Amgen Inc. today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a chronic and serious autoimmune disorder characterized by lower than expected platelet counts in the blood, sometimes leading to serious bleeding events. The results were presented today as an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH Abstract # 402). Results from a study of Nplate in myelodysplastic syndromes (MDS) also were presented. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054887 Mon, 08 Dec 2008 05:00:00 +0100 2054887 http://www.medworm.com/index.php?rid=2054888&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnplatetm_romiplostim_receives_positive_opinion_for_marketing_authorisation_%2F THOUSAND OAKS, Calif. – Nov. 21 – Amgen (Nasdaq: AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU). The CHMP recommends Nplate for adult chronic immune (idiopathic) thrombocytopenia purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054888 Fri, 21 Nov 2008 05:00:00 +0100 2054888 http://www.medworm.com/index.php?rid=2054889&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_takeda_and_millennium_provide_update_on_phase_3_trial_of_motesanib_in%2F THOUSAND OAKS, Calif., Nov. 19  – Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study’s independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054889 Wed, 19 Nov 2008 05:00:00 +0100 2054889 http://www.medworm.com/index.php?rid=2054890&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_foundation_announces_25_million_expansion_of_amgen_scholars_program_t%2F Hands-On Science Research Program Expansion Brings the Amgen Foundation’s Total Commitment to Amgen Scholars to $27.5 Million Applications for 2009 Amgen Scholars U.S. Program Now Available THOUSAND OAKS, Calif. – Nov. 10, 2008 – Each year, hundreds of students from across the United States (U.S.) participate in the Amgen Scholars Program under renowned faculty members at the country’s leading universities. Now, the same opportunity will be extended to undergraduates throughout Europe. As part of its mission to advance science education, the Amgen Foundation, in partnership with three of Europe’s leading universities, today announced the launch of the Amgen Scholars Program in Europe. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=2054890 Mon, 10 Nov 2008 05:00:00 +0100 2054890 http://www.medworm.com/index.php?rid=1941202&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_positioned_to_deliver_attractive_growth_over_next_five_years%2F NEW YORK – Nov 07, 2008 – At an Amgen (Nasdaq: AMGN) meeting of about 200 securities analysts and investors in New York City today, several members of its senior management team outlined the Company’s growth strategy, which includes delivering on its pipeline—including the experimental bone drug denosumab—growing in-line products and continuing to pursue operating efficiencies. "In 2001, Amgen had two blockbuster products and today we have five blockbusters on the market," said Amgen Chairman and CEO Kevin Sharer. "Over the next five years we could have three more drugs achieve blockbuster status: Sensipar(R) (cinacalcet), denosumab for osteoporosis and denosumab for cancer-related indications." (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1941202 Fri, 07 Nov 2008 05:00:00 +0100 1941202 http://www.medworm.com/index.php?rid=1941203&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fcall_for_applications_the_amgen_award_for_science_teaching_excellence%2F THOUSAND OAKS, Calif. – Nov. 3 – Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 18th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1941203 Mon, 03 Nov 2008 05:00:00 +0100 1941203 http://www.medworm.com/index.php?rid=1941204&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fenbrelr_etanercept_is_the_first_biologic_with_published_efficacy_and_safety%2F SAN FRANCISCO – Oct. 27 – Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that ENBREL is the first biologic with published clinical trial data to show sustained improvements in multiple measures of efficacy in moderate to severe rheumatoid arthritis (RA) patients completing up to 10 years of therapy. In this analysis, the safety profile remained consistent with continuous ENBREL use for up to 10 years. These new data are being presented at the American College of Rheumatology (ACR) Scientific Meeting in San Francisco. (Abstract 1007; Poster Board 268) (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1941204 Mon, 27 Oct 2008 04:00:00 +0100 1941204 http://www.medworm.com/index.php?rid=1903623&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_third_quarter_2008_adjusted_earnings_per_share_increased_14_percent_%2F Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from Third Quarter 2007 GAAP Earnings Per Share of $0.18 Full Year Revenue Guidance Raised from $14.6 Billion - $14.9 Billion to $14.9 Billion - $15.2 Billion Full Year Adjusted EPS Guidance Raised from $4.25 - $4.45 to $4.45 - $4.55 THOUSAND OAKS, Calif., Oct. 22 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.23 for the third quarter of 2008, an increase of 14 percent compared to $1.08 for the third quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, increased 11 percent to $1,308 million in the third quarter of 2008 compared t... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1903623 Wed, 22 Oct 2008 04:00:00 +0100 1903623 http://www.medworm.com/index.php?rid=1866517&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_issues_statement_on_court_of_appeals_ruling_that_affirms_preliminary_%2F THOUSAND OAKS, Calif. – Today the United States (U.S.) Court of Appeals for the Federal Circuit issued a ruling that affirms the preliminary injunction ordered by the U.S. District Court in Boston barring Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1866517 Fri, 10 Oct 2008 04:00:00 +0100 1866517 http://www.medworm.com/index.php?rid=1866518&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_francois_de_carbonnel_to_the_companys_board_of_directors%2F THOUSAND OAKS, Calif. – Oct 03, 2008 – Amgen (NASDAQ:AMGN) announced today that its Board of Directors has appointed Francois de Carbonnel to the Company’s Board. Mr. de Carbonnel, 61, is a consultant and corporate financial advisor. He is also chairman of the board of Thomson S.A. (Euronext Paris:18453; NYSE:TMS), an international multimedia corporation. He is also a member of the boards of Pages Jaunes S.A., a French public company, Quilvest S.A., a public Luxembourg company, Ecofin Global Utilities Hedge Fund Ltd. and Ecofin North America Utilities Hedge Fund Ltd., both Irish public companies. His appointment brings the number of Amgen Board members to 12. Mr. de Carbonnel will serve as a member of the Audit and Governance and Nominating Committees of the Board. (Source: A... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1866518 Fri, 03 Oct 2008 04:00:00 +0100 1866518 http://www.medworm.com/index.php?rid=1849109&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdistrict_court_affirms_patent_infringement_rulings%2F THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) announced today that the United States (U.S.) District Court in Boston issued its written decision upholding the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen’s erythropoietin (EPO) patents. The Court also ruled that Amgen is entitled to a permanent injunction prohibiting Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S. Previously, the Court entered a preliminary injunction preventing Roche from selling peg-EPO, and Roche has appealed that ruling. In today’s decision, the District Court stated that it would enter a permanent injunction once the appeal of the preliminary injunction is resolved. (Source: Amgen News Servic... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1849109 Thu, 02 Oct 2008 04:00:00 +0100 1849109 http://www.medworm.com/index.php?rid=1842076&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_receives_executive_summary_from_independent_cochrane_collaboration_re%2F THOUSAND OAKS, Calif., – Sep 30, 2008 – Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1842076 Tue, 30 Sep 2008 04:00:00 +0100 1842076 http://www.medworm.com/index.php?rid=1795623&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_osteoporosis_trial_finds_patients_transitioned_from_alendronate%2F Additional Data From Separate Head-to-Head Trial Showed More Than 75 Percent of Patients Prefer the Administration and Frequency of Twice-Yearly Subcutaneous Injection Compared to Weekly Oral Pill MONTREAL – Sept. 15, 2008 – Amgen (NASDAQ:AMGN) today announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy. In addition, patient preference data from another non-pivotal head-to-head trial comparing denosumab to weekly oral alendronate were announced today at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Montreal. ... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1795623 Mon, 15 Sep 2008 04:00:00 +0100 1795623 http://www.medworm.com/index.php?rid=1792326&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fbiovitrum_to_acquire_kepivancer_and_stemgenr_and_exclusively_license_kinere%2F STOCKHOLM, Sweden & THOUSAND OAKS, Calif. – Sept. 15, 2008 – Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance(R) (palifermin) and Stemgen(R) (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret(R) (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1792326 Mon, 15 Sep 2008 04:00:00 +0100 1792326 http://www.medworm.com/index.php?rid=1786829&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_important_clinical_trial_data_at_two_key_congresses%2F New Denosumab Osteoporosis Data at ASBMR Denosumab Oncology and Oncology Therapeutics Data at ESMO THOUSAND OAKS, Calif. – Sept. 11, 2008 – Amgen (NASDAQ:AMGN) today announced it will present new data from osteoporosis studies of its investigational therapy, denosumab, at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting that will be held in Montreal, Sept. 12-16, 2008. Additionally, data from the denosumab oncology program and the oncology therapeutics portfolio of marketed and pipeline products will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress in Stockholm, Sweden, Sept. 12-16, 2008. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1786829 Thu, 11 Sep 2008 04:00:00 +0100 1786829 http://www.medworm.com/index.php?rid=1786830&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_wyeth_statement_on_tumor_necrosis_factor_tnf_blockers%2F THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa. – Sept. 4, 2008 – Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab) and Cimzia(R) (certolizumab pegol)). (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1786830 Thu, 04 Sep 2008 04:00:00 +0100 1786830 http://www.medworm.com/index.php?rid=1772137&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_approves_nplatetm_for_long_term_treatment_of_adult_chronic_itp%2F First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen to Launch Nplate(TM) NEXUS Program to Provide Treatment Access and Patient Support Programs THOUSAND OAKS, Calif. –Aug 22, 2008 – Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic disease. (Source: Amgen N... Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772137 Fri, 22 Aug 2008 04:00:00 +0100 1772137 http://www.medworm.com/index.php?rid=1772138&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_licenses_molecule_for_the_treatment_of_chronic_and_neuropathic_pain_t%2F  THOUSAND OAKS, Calif. – July 31, 2008 – Amgen (NASDAQ: AMGN) today announced that it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. The terms of the agreement include a $50 million upfront payment, the potential for $385 million in success-based milestones and additional sales based milestones and royalties on sales. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772138 Thu, 31 Jul 2008 04:00:00 +0100 1772138 http://www.medworm.com/index.php?rid=1772139&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_issues_statement_in_response_to_revised_esa_labeling_from_the_fda%2F Amgen issued the following statement in response to the receipt today of the complete response on the revised ESA labeling from the FDA. “This label is consistent with our expectations.  We will soon be communicating the revised product labeling for ESAs to both physicians and patients.” The potential impact of this revised label was factored into our updated guidance announced July 28, 2008. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772139 Wed, 30 Jul 2008 04:00:00 +0100 1772139 http://www.medworm.com/index.php?rid=1772140&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_positive_top_line_results_for_denosumab_pivotal_postmenopau%2F Study Met Primary Endpoint of Reducing New Vertebral Fractures and Secondary Endpoints of Reducing Time to First Non-Vertebral and Hip Fractures; Adverse Events Similar to Placebo THOUSAND OAKS, Calif. – July 25, 2008 – Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772140 Fri, 25 Jul 2008 04:00:00 +0100 1772140 http://www.medworm.com/index.php?rid=1772141&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnplate_update%2F The FDA notified Amgen that they will not issue a decision on Nplate™ (romiplostim) by the PDUFA deadline of July 23, 2008. Amgen continues to work with the FDA to assist in the completion of the review process. We remain optimistic that a final decision will be made soon, but Amgen cannot speculate on the timing of the FDA’s response. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772141 Wed, 23 Jul 2008 04:00:00 +0100 1772141 http://www.medworm.com/index.php?rid=1772142&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2F250_amgen_scholars_from_10_premier_universities_convene_for_national_summer%2F THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. – July 21, 2008 – From July 19-21, nearly 250 undergraduate students from across the country gathered at the University of California, Los Angeles (UCLA) to share their summer research projects and gain insight into how scientific research can translate into the discovery and development of important drugs for patients. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772142 Mon, 21 Jul 2008 04:00:00 +0100 1772142 http://www.medworm.com/index.php?rid=1772143&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2008_second_quarter_financial_results%2F THOUSAND OAKS, Calif., Jul 17, 2008 – Amgen (NASDAQ:AMGN) today announced that it plans to report its second quarter financial results on Monday, July 28, 2008 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772143 Thu, 17 Jul 2008 04:00:00 +0100 1772143 http://www.medworm.com/index.php?rid=1772144&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Factive_early_rheumatoid_arthritis%2F COLLEGEVILLE, Pa. & THOUSAND OAKS, Calif. – July 15, 2008 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Amgen (NASDAQ:AMGN) today announced the publication of data from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial demonstrating that half of patients treated with the combination of ENBREL and methotrexate achieved Disease Activity Score (DAS) clinical remission and nearly all had no progression of joint damage. These findings were published online on July 15 by The Lancet, a leading global medical journal. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772144 Tue, 15 Jul 2008 04:00:00 +0100 1772144 http://www.medworm.com/index.php?rid=1772146&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_positive_top_line_results_for_denosumab_treatment_of_bone_l%2F  Data From First Pivotal Study in Men Met Primary Endpoint of Increases in Bone Mineral Density and Secondary Endpoint of New Vertebral Fracture Reduction THOUSAND OAKS, Calif. – Jul 14, 2008 – Amgen (NASDAQ:AMGN) today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772146 Mon, 14 Jul 2008 04:00:00 +0100 1772146 http://www.medworm.com/index.php?rid=1772145&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fbusiness_wire_issues_retraction_of_nplate_press_release%2F Business Wire requests that BW5644, Amgen Inc. press release entited "FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP" be killed. The release was issued prematurely by Business Wire. (Source: Amgen News Service) Amgen News Service organizations http://www.medworm.com/rss/comments.php?id=1772145 Mon, 14 Jul 2008 04:00:00 +0100 1772145